| Andrew Moraco, MD | |
|
77 Warren St Fl 2, Brighton, MA 02135-3601 | |
| (617) 789-2545 | |
| Not Available |
| Full Name | Andrew Moraco |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 14 Years |
| Location | 77 Warren St Fl 2, Brighton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740500560 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 258044 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Elizabeth's Medical Center | Brighton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
News Archive
Working with a nanoparticle designed to target and image glioblastoma, a form of brain cancer, investigators at the University of Washington in Seattle have found that these same nanoparticles inhibit tumor cell invasion, one of the key events that leads to the metastatic spread of cancer. The investigators have also determined how the nanoparticles exert this potentially beneficial effect.
Mums to be have known for some time that what they eat when pregnant affects their unborn child but now scientists believe that the diet of our mothers during pregnancy may even affect our predisposition to illnesses such as heart disease, diabetes and high blood pressure in late life.
Upon sexual exposure, the AIDS virus must overcome some mighty barriers to find the right target cell and establish a new infection.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
Rick Schmitt reports for Kaiser Health News on how unemployed workers are faring with their COBRA subsidies. "In the past very few people could afford this option, but the government subsidies have changed that, and now enrollments appear to be growing sharply. Hewitt Associates, a Lincolnshire, Ill., consulting firm, recently estimated that the rate at which workers were opting for coverage under COBRA had doubled compared with pre-subsidy levels.
› Verified 5 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000007 |
News Archive
Working with a nanoparticle designed to target and image glioblastoma, a form of brain cancer, investigators at the University of Washington in Seattle have found that these same nanoparticles inhibit tumor cell invasion, one of the key events that leads to the metastatic spread of cancer. The investigators have also determined how the nanoparticles exert this potentially beneficial effect.
Mums to be have known for some time that what they eat when pregnant affects their unborn child but now scientists believe that the diet of our mothers during pregnancy may even affect our predisposition to illnesses such as heart disease, diabetes and high blood pressure in late life.
Upon sexual exposure, the AIDS virus must overcome some mighty barriers to find the right target cell and establish a new infection.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
Rick Schmitt reports for Kaiser Health News on how unemployed workers are faring with their COBRA subsidies. "In the past very few people could afford this option, but the government subsidies have changed that, and now enrollments appear to be growing sharply. Hewitt Associates, a Lincolnshire, Ill., consulting firm, recently estimated that the rate at which workers were opting for coverage under COBRA had doubled compared with pre-subsidy levels.
› Verified 5 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
Working with a nanoparticle designed to target and image glioblastoma, a form of brain cancer, investigators at the University of Washington in Seattle have found that these same nanoparticles inhibit tumor cell invasion, one of the key events that leads to the metastatic spread of cancer. The investigators have also determined how the nanoparticles exert this potentially beneficial effect.
Mums to be have known for some time that what they eat when pregnant affects their unborn child but now scientists believe that the diet of our mothers during pregnancy may even affect our predisposition to illnesses such as heart disease, diabetes and high blood pressure in late life.
Upon sexual exposure, the AIDS virus must overcome some mighty barriers to find the right target cell and establish a new infection.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
Rick Schmitt reports for Kaiser Health News on how unemployed workers are faring with their COBRA subsidies. "In the past very few people could afford this option, but the government subsidies have changed that, and now enrollments appear to be growing sharply. Hewitt Associates, a Lincolnshire, Ill., consulting firm, recently estimated that the rate at which workers were opting for coverage under COBRA had doubled compared with pre-subsidy levels.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Moraco, MD 77 Warren St, 2nd Fl, Brighton, MA 02135 Ph: (617) 789-2545 | Andrew Moraco, MD 77 Warren St Fl 2, Brighton, MA 02135-3601 Ph: (617) 789-2545 |
News Archive
Working with a nanoparticle designed to target and image glioblastoma, a form of brain cancer, investigators at the University of Washington in Seattle have found that these same nanoparticles inhibit tumor cell invasion, one of the key events that leads to the metastatic spread of cancer. The investigators have also determined how the nanoparticles exert this potentially beneficial effect.
Mums to be have known for some time that what they eat when pregnant affects their unborn child but now scientists believe that the diet of our mothers during pregnancy may even affect our predisposition to illnesses such as heart disease, diabetes and high blood pressure in late life.
Upon sexual exposure, the AIDS virus must overcome some mighty barriers to find the right target cell and establish a new infection.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
Rick Schmitt reports for Kaiser Health News on how unemployed workers are faring with their COBRA subsidies. "In the past very few people could afford this option, but the government subsidies have changed that, and now enrollments appear to be growing sharply. Hewitt Associates, a Lincolnshire, Ill., consulting firm, recently estimated that the rate at which workers were opting for coverage under COBRA had doubled compared with pre-subsidy levels.
› Verified 5 days ago
Dr. Mahendra Carpen, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge St, Dept. Of Cardiology, Brighton, MA 02135 Phone: 617-789-5151 | |
Syed Kashif Mahmood, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 11 Nevins St Ste 406, Brighton, MA 02135 Phone: 617-562-5432 Fax: 617-789-5049 | |
Brian Ash, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Mob 505, Brighton, MA 02135 Phone: 617-782-5316 | |
Mikhail Mayskiy, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Ccp4c, Brighton, MA 02135 Phone: 617-789-2060 Fax: 617-789-5029 | |
Lawrence A. Kenney, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge St, Seton Pavillion, 3rd Floor, Brighton, MA 02135 Phone: 617-789-2548 Fax: 617-562-7756 | |
Nikolay Korchemny, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge Street, Office Of Gme, Brighton, MA 02135 Phone: 617-789-2386 | |
Harry Dinerman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Mmr 3 Iiem/one, Brighton, MA 02135 Phone: 617-789-3081 Fax: 617-789-3349 |